THE EFFECTS OF SOLIFENACIN ON CARBACHOL-INDUCED CONTRACTION IN HUMAN BLADDER SMOOTH MUSCLES IN NORMAL STATE AND IN DETRUSOR OVERACTIVITY ASSOCIATED WITH BENIGN PROSTATIC HYPERPLASIA

Hypothesis / aims of study
Detrusor overactivity is noted in 50-70% of benign prostatic hyperplasia (BPH). Solifenacin is a muscarinic antagonist that has selectivity for M3 and M1 muscarinic receptor subtypes and thus is effective for the treatment of overactive bladder. It has been reported that M3 muscarinic receptor (MR) subtypes mainly mediate contraction in normal bladder. It has also been reported that M2-receptors participate in the contractile response under pathologic conditions in both rat and human detrusor smooth muscles [1]. M2-receptors have been reported to mediate contraction in the rat with pelvic nerve denervation or spinal cord transaction, and in patients with neurogenic bladder dysfunction [2, 3]. The aim of the present study is to compare the antagonist affinities of solifenacin against carbachol-induced contraction in human detrusor muscles between normal state and detrusor overactivity due to BPH (BPH/DO).

Study design, materials and methods
Tissue samples of human bladder muscles were obtained from patients undergoing total cystectomy due to bladder cancer (normal bladder, n=8), and those undergoing prostatectomy due to benign prostatic hyperplasia (BPH/DO, n=6). All of the patients with BPH/DO had detrusor overactivity in video-urodynamic studies or ambulatory urodynamics before the surgery. Tissues were mounted in 10 ml organ baths containing Krebs solution, and concentration-response curves (CRCs) to carbachol were obtained. After incubation for 30 minutes, a second CRC to carbachol was constructed in the continued presence of antagonist or vehicle. In this way, 4 CRCs to carbachol were obtained from the same strip, three in the presence of increasing concentrations of solifenacin (3, 10, 30nM) or in the presence of vehicle. The study has been conducted in accord with the Helsinki Declaration. The procedures have been approved by the local ethics committee, and written informed consent was obtained from each patient before entry into the study.

Results
Carbachol produced concentration-dependent contraction with mean pEC50 values and maximum responses of 6.56±0.18 and 9.55±0.72g, respectively, in the normal bladder. Carbachol also produced concentration-dependent contraction of the human urinary bladder with BPH/DO with mean pEC50 values and maximum responses of 5.75±0.04 and 9.79±1.7g, respectively. Solifenacin produced parallel, rightward displacement of the CRCs to carbachol without affecting maximum responses. On Schild plot Mean (±SEM) pA2 values in normal bladder and BPH/DO were 8.80±0.10 and 8.73±0.09, respectively.

Interpretation of results
Solifenacin, a M3 and M1 muscarinic receptor subtype selective antagonist antagonized CRCs to carbachol with high affinities. Antagonist affinities of solifenacin did not change in bladder smooth muscle with BPH/DO.

Concluding message
Solifenacin inhibits bladder smooth muscle contraction induced by muscarinic receptor stimulation with high affinity both in the normal state and in overactive bladder associated with BPH.

References

Figure: Effects of solifenacin on CRCs to carbachol in normal bladder (upper panel) and BPH/DO (lower panel)

Specify source of funding or grant
Is this a clinical trial? None

What were the subjects in the study? ANIMAL

Were guidelines for care and use of laboratory animals followed or ethical committee approval obtained? No

Statement that no ethical approval was needed
Considering that the tissues were obtained from animals killed at a local abattoir, the protocol was thought to be ethical.